Cor Vasa 2021, 63(1):6-10 | DOI: 10.33678/cor.2020.063
Efficacy and safety of non-vitamin K antagonist oral anticoagulants one year after electrical cardioversion
- a Riga East University Hospital, Riga, Latvia
- b Department of Internal Medicine, Riga Stradins University, Riga, Latvia
- c Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital, Riga, Latvia
- d Faculty of Medicine, Riga Stradins University, Riga, Latvia
Introduction: Atrial fibrillation (AF) is the most common arrhythmia in the world, affecting around 33 million people. Warfarin has been the anticoagulant of choice for the prevention of ischemic stroke in AF patients for a long time. Several large studies have shown that non-vitamin K antagonist oral anticoagulants (NOACs) offer numerous advantages regarding safety and effectiveness, such as fixed dose and more predictable pharmacokinetics.
Methods: The study was conducted at Pauls Stradins Clinical University Hospital, Latvian Centre of Cardiology. The study took place from October 2015 to June 2017. A total of 356 patients who had undergone electrical cardioversion (ECV) was included in this study.
Results: One year after ECV, 27.5% of patients used warfarin, 33.7% of patients used NOACs, whereas 38.8% did not use any oral anticoagulants. Nine (2.5%) of the patients who participated in the study died during the following year. Overall, eight patients (2.2%) suffered from significant bleeding and three patients (0.8%) had a non-fatal ischemic stroke. The rate of non-fatal ischemic stroke in patients who used warfarin was 2% and no cases were observed in patients who used NOACs (p = 0.20). The rate of significant bleeding was 5.1% versus 2.5% in warfarin and NOAC groups, respectively (p = 0.12).
Conclusions: Compared with similar studies, our study showed a low rate of ischemic stroke and significant bleeding, and a low total death rate. One year after ECV, the use of warfarin decreased by 2.8% (p = 0.63), the use of rivaroxaban and dabigatran decreased by 17.5% (p = 0.001) and 17.4% (p = 0.001). The study shows that NOACs are a safe and effective alternative to warfarin.
Keywords: Atrial fibrillation, Electrical cardioversion, Oral anticoagulants
Received: April 17, 2020; Revised: June 18, 2020; Accepted: June 21, 2020; Published: February 25, 2021 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease Study. Circulation 2014;129:837-847.
Go to original source...
Go to PubMed...
- Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042-1046.
Go to original source...
Go to PubMed...
- Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-988.
Go to original source...
Go to PubMed...
- Stewart S, Murphy N, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286-292
Go to original source...
Go to PubMed...
- Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC), Eur Heart J 2016;37:2893-2962.
Go to original source...
Go to PubMed...
- Weinberg DM, Mancini J. Anticoagulation for cardioversion of atrial fibrillation. Am J Cardiol 1989;63:745-746.
Go to original source...
Go to PubMed...
- Nuotio I, Hartikainen JE, Gronberg. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA 2014;312:647-649.
Go to original source...
Go to PubMed...
- Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.
Go to original source...
Go to PubMed...
- Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
Go to original source...
Go to PubMed...
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151.
Go to original source...
Go to PubMed...
- Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131:157-164.
Go to original source...
Go to PubMed...
- Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-962.
Go to original source...
Go to PubMed...
- Apostolakis S, Haeusler KG, Oeff M, et al. Low stroke risk after elective cardioversion of atrial fibrillation: an analysis of the Flec-SL trial, International Journal of Cardiology 2013;168:3977-3981.
Go to original source...
Go to PubMed...
- Femia G, Fetahovic T, Shetty P, Lee A. Novel Oral Anticoagulants in Direct Current Cardioversion for Atrial Fibrillation. Heart Lung Circ 2018;7:798-803.
Go to original source...
Go to PubMed...
- Shin DG, Cho I, Hartaigh Bó, et al. Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis Yonsei Med J 2015;56:1552-1558.
Go to original source...
Go to PubMed...
- Cios DA, Baker WL, Sander SD, et al. Evaluating the Impact of Study-Level Factors on Warfarin Control in U.S.-based Primary Studies: A Meta-Analysis. Am J Health Syst Pharm 2009;66:916-925
Go to original source...
Go to PubMed...
- Stampfuss J, Kubitza D, Becka M, Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 2013;7:549-561.
Go to original source...
Go to PubMed...
- Barrett A, Moore M, Ferrins P, et al. From a Direct Oral Anticoagulant to Warfarin: Reasons Why Patients Switch. Ir J Med Sci 2018;187:719-721.
Go to original source...
Go to PubMed...
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.